Selgantolimod

DB16324InvestigationalSmall molecule

Selgantolimod is under investigation in clinical trial NCT03491553 (Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-suppressed Adults With Chronic Hepatitis B).

Mechanism: Pharmacologically active on Toll-like receptor 8
Curator reviewed
Formula / weight: C₁₄H₂₀FN₅O · 293.346 g/mol (avg)
Code names: GS-9688

Resolves to

Compound

UNIIRM4GJT3SMQCAS2004677-13-6ChEMBLCHEMBL4297614

Structure

InChIKeyHTCJUBZBSJQWBW-AWEZNQCLSA-NSMILESCCCC[C@@](C)(CO)NC1=NC(N)=NC2=C1N=CC(F)=C2

Targets

Q9NR97TLR8

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Selgantolimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account